Published: 2011-01-12 13:29:20 CET

Exiqon releases second generation human and mouse microRNA inhibitor libraries

Copenhagen, Denmark, 2011-01-12 13:29 CET (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of the 2nd generation of miRCURY LNA™ microRNA Inhibitor libraries for genome-wide screening of microRNA function in human and mouse. Several libraries have already been shipped to the first customers.

The new human microRNA inhibitor library targets almost 1,000 different microRNAs which makes it the library with the highest coverage on the market. The human library also targets 40 proprietary miRPlus™ microRNAs. The new mouse library likewise has the highest coverage as it targets more than 700 microRNAs.

“By use of our proprietary LNA™ technology we have been able to design highly potent microRNA inhibitors with uniform and specific affinity for their targets which is critical for successful high throughput screenings”, said Vice President Sales & Marketing, Dr. Henrik M. Pfundheller and added: “Due to the high potency caused by the high affinity and biostability of the LNA™, the microRNA inhibitors may be applied at very low concentrations minimizing problems with secondary effects”.

Information about the miRCURY LNA™ microRNA Inhibitor products is available at Exiqon’s website:
http://www.exiqon.com/mirna-inhibitor

Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)

See the full release in the attached PDF or at www.exiqon.com/investor/portal

 


PressRelease_InhibitorLibrary_110112.pdf